Bybit executive shares vision for regulation, tokenisation and institutional trust at LEAP East 2026
DUBAI, UAE, July 13, 2026 /PRNewswire/ -- As digital assets move beyond early adoption and into the portfolios of global financial institutions, the defining question is no longer whether blockchain technology works, but whether institutions can trust the infrastructure behind it.
That was the central message delivered by Yoyee Wang, Global Head of TradFi and Real-World Assets (RWA) at Bybit, during a featured panel discussion at LEAP East 2026, where policymakers, financial institutions and technology leaders explored how trust is becoming the foundation of next-generation financial systems.
Speaking on the panel, "Trust Is the New Infrastructure: Security, Identity, Fraud & Regulation at Scale," Yoyee outlined why regulation, client-first product design and practical real-world applications are becoming the key drivers of institutional adoption.
"Institutional adoption has never been about chasing the highest returns," said Yoyee. "For professional investors, trust begins with capital preservation, regulatory certainty and infrastructure they can rely on. When those foundations are in place, innovation becomes far easier to embrace."
Drawing on Bybit's experience serving institutional clients globally, Yoyee observed that regulation has evolved from being viewed primarily as a compliance obligation into a strategic differentiator.
She noted that regulatory clarity provides confidence for existing clients to deepen their participation in digital assets while also encouraging new institutions to begin exploring the asset class. As more major jurisdictions establish clear frameworks, institutions are increasingly willing to allocate portions of their portfolios to digital assets, expanding participation across the broader ecosystem.
"Trust is built over time," Yoyee explained. "Institutions don't suddenly move significant capital into a new asset class. They start with measured allocations, validate the infrastructure, and gradually increase exposure as confidence grows. That's how every financial market matures."
The discussion also explored the rapid emergence of tokenised real-world assets (RWAs) and the convergence between traditional finance and blockchain-based markets.
According to Yoyee, the industry's role is not to persuade institutions to adopt blockchain, but to ensure the right infrastructure is ready when they decide the time is right.
"At Bybit, we see ourselves as infrastructure builders," Yoyee said. "Our responsibility is to understand what institutional clients are trying to achieve and provide solutions that address those needs while maintaining the standards of security, governance and operational resilience they expect."
Rather than focusing solely on yield opportunities, Yoyee highlighted that many traditional financial institutions prioritise protecting principal while seeking operational efficiencies. This shift is shaping how digital asset platforms design products for institutional investors.
She pointed to tokenised money market funds as one example where blockchain technology can enhance existing financial products by enabling clients holding on-chain assets such as stablecoins to access returns traditionally available in conventional financial markets, while maintaining flexibility over how they allocate capital.
"Technology should expand choice, not replace it," Yoyee said. "Tokenisation gives institutions additional options to manage liquidity and capital more efficiently. Whether they adopt those solutions is ultimately their decision. Our role is to provide secure, trusted access when they're ready."
Throughout the discussion, Yoyee emphasised that successful institutional adoption depends on understanding clients' underlying objectives rather than simply introducing new technology.
As digital assets become increasingly integrated into mainstream finance, she argued that long-term success will belong to platforms capable of combining regulatory excellence, trusted infrastructure and deep collaboration with financial institutions.
#NewFinancialPlatform
//ENDS
About Bybit
Bybit is The New Financial Platform.
We believe every person should have access to every financial opportunity on earth. That's why we're building the first intelligent platform that connects anyone, anywhere to the world's finance.
Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.
Built for everyone. Powered by intelligence. Open to the world.
Learn more at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Bybit's Yoyee Wang: Trust Will Define the Next Era of Institutional Digital Asset Adoption
SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stage clinical pipelines, business development strategies, M&A trends, multinational collaboration models, and global licensing transactions.
ACROBiosystems participated as a key strategic partner under the theme "Enabling Global Opportunity," working with a broad network of industry partners to build a strategic partnering platform for the globalization of innovation assets. The event gathered more than 200 participants from over 30 countries, creating a highly active environment for business dialogue and partnering discussions.
During the summit, ACROBiosystems set up a dedicated networking lounge to provide attendees with an exclusive space for in-depth discussion, helping turn thought leadership and ideas into tangible collaboration.
As innovative drug development becomes increasingly global, ACROBiosystems is further leveraging its global customer network, technical service capabilities, industry insight, and ecosystem connectivity to advance its role as a global strategic partner for innovation. Through the summit, ACROBiosystems aims to amplify the visibility of high-potential innovation assets and help them gain greater international recognition, deeper industry understanding, and more partnering opportunities during a critical window for the global biopharmaceutical industry.
From winter to summer, ACROBiosystems has continued to advance global innovation partnerships. Following the BIOSeedin Winter Innovation Partnering Summit in San Francisco this January and the BIOSeedin Spring Innovation Partnering Summit in Shanghai this May, the BIOSeedin Summer Innovation Partnering Summit in San Diego further extended this momentum. Besides, ACROBiosystems has also hosted ACRO Innovation Day and the ACRO Innovation Forum in Europe and Shanghai, reinforcing its commitment to empowering the industry and building platforms for innovation exchange.
Looking ahead, ACROBiosystems will continue to work with global partners around its core brand values of "Reliable Quality, Integrated Innovation, and Considerate Service", jointly accelerating the translation of biopharmaceutical innovation into clinical applications and global markets.
Summit Recap
The summit opened with remarks from Ms. Jenny Zhao, Co-founder and CEO of bioSeedin.
And then the summit went on with panels and company presentations, along with one on one partnering session to motivate exchange and precision collaborations.
The panel session split into two parts: the early-stage and late-stage session.
No. 1 Early-Stage Session
The Early-Stage Session featured two panel discussions on licensing, external innovation, and M&A. The first panel brought together executives from Debiopharm, Otsuka Pharmaceutical, Roche/Genentech, AstraZeneca.
Key Takeaways:
- Licensing is not simply an asset transaction, but a strategic tool for translating differentiated science into long-term value.
- Strong biology, high-quality data, translational continuity, and a credible global clinical development plan remain essential to deal execution.
- Deals often stall due to weak biological rationale, unclear patient or biomarker strategies, poor PK/PD or therapeutic windows, and inadequate global development planning.
The second panel was moderated by Kenneth C. Chen, Senior Director of Business Development, US & EU, at bioSeedin, and featured executives from Sun Pharma, Hygieia Pharma, and Servier.
Key Takeaways:
- M&A should support long-term corporate strategy rather than serve as an end goal.
- Companies need to balance acquisitions, strategic investments, and licensing transactions.
- Successful M&A depends on valuation discipline, rigorous due diligence, effective execution, and post-deal integration.
The session also included company presentations from Antengene, GeneScience Pharmaceutical, and Salsola Therapeutics, showcasing innovative pipelines across autoimmune diseases, immunology, and neuropsychiatric disorders.
No. 2 Late-Stage Session
The Late-Stage Session Executives from Daiichi Sankyo, Takeda, Boehringer Ingelheim, and Thermo Fisher Scientific discussed the global innovation ecosystem and emerging industry trends.
Key Takeaways:
Innovation must remain grounded in strong science, robust biology, high-quality data, and rigorous R&D.
China and AI are long-term structural forces rather than short-term trends. Companies need a clear and coherent China strategy.
AI can support the full R&D value chain, but it cannot replace scientific fundamentals.
The session also featured presentations from HighTide Therapeutics, Constimulus Bio, CanWell Pharma, Jiangsu Chia Tai Fenghai Pharmaceutical, Amphiprotech, and VyBio, showcasing advanced pipelines and global development opportunities across multiple therapeutic areas.
About ACROBiosystems Group:
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models. The company spans across the globe and maintains offices, R&D centers, and production bases in more than 15 different cities within the United States, Switzerland, the United Kingdom and Germany. ACROBiosystems Group has established numerous long-term and stable partnerships with the world's top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.
ACROBiosystems' brands include Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, GENPower and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.
Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and their clinical applications, and contributes to global health.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
